ライフサイエンスコーパス: nab-paclitaxel

1 ion of the antimicrotubular drug Paclitaxel (nab-paclitaxel).

2 Cav-1 overexpression enhanced sensitivity to nab-paclitaxel.

3 interaction that enables antibody coating of nab-paclitaxel.

4 d in the cancers noted above that respond to nab-paclitaxel.

5 d in the experimental arms, particularly for nab-paclitaxel.

6 rforms more efficaciously than docetaxel and nab-paclitaxel.

7 anisms of delivery and antitumor activity of nab-paclitaxel.

8 atin (area under the curve of 2, weekly) and nab-paclitaxel (100 mg/m(2) weekly) with vorinostat (400

9 NAB-paclitaxel 125 mg/m(2) administered on days 1, 8, an

10 res indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface

11 acizumab with paclitaxel 90 mg/m(2) (arm A), nab-paclitaxel 150 mg/m(2) (arm B), or ixabepilone 16 mg

12 on of PFS (> 5 months) in patients receiving nab-paclitaxel 150 mg/m(2) weekly compared with docetaxe

13 nab-Paclitaxel 150 mg/m(2) weekly demonstrated significa

14 Patients received nab-paclitaxel 260 mg/m(2) administered intravenously fo

15 0 mg/m(2) for 14 days), taxane (Tax) -based (nab-paclitaxel 260 mg/m(2), docetaxel 75 or 100 mg/m(2))

16 Nab-paclitaxel, a nanoparticle conjugate of paclitaxel t

17 Previously we described three nab-paclitaxel (Abraxane) nanoparticles coated with comm

18 -covalently bound to the albumin scaffold of nab-paclitaxel (ABX).

19 y contribute to the preclinical finding that nab-paclitaxel achieves a 33% higher tumor uptake relati

20 gemcitabine plus nanoparticle albumin-bound (NAB) -paclitaxel (adequate comorbidity profile) should b

21 ated dose (MTD) and single-agent activity of NAB-paclitaxel administered on a weekly basis to patient

22 , respectively, whereas native docetaxel and nab-paclitaxel (albumin-paclitaxel nanoparticle, Abraxan

23 ice with human pancreatic cancer xenografts, nab-paclitaxel alone and in combination with gemcitabine

24 ally, a possible mechanistic synergy between nab-paclitaxel and capecitabine has been cited as the ra

25 small molecule (doxorubicin), nanoparticles (nab-paclitaxel and doxorubicin liposomes), and a monoclo

26 s a predictive biomarker for the response to nab-paclitaxel and other albumin-based cancer therapeuti

27 Thus, nab-paclitaxel appears to interact with tumors in a numb

28 ecan, and oxaliplatin as well as gemcitabine/nab-paclitaxel are active in the metastatic setting, the

29 plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) are the treatments of choice for patient

30 ebrile neutropenia were less frequent in all nab-paclitaxel arms.

31 Additional studies of single-agent NAB-paclitaxel as well as platinum-based combinations ar

32 total of 20, 44, and three patients received nab-paclitaxel at 100, 125, and 150 mg/m(2), respectivel

33 nm fluorphore was chosen as a surrogate for nab-paclitaxel based on its similar molecular weight and

34 particles could allow reverse engineering of nab-paclitaxel binding antibodies, creating a modular pl

35 and safety of weekly and every 3 week (q3w) nab-paclitaxel compared with docetaxel as first-line tre

36 rated superior efficacy and safety of weekly nab-paclitaxel compared with docetaxel, with a statistic

37 for patients receiving either dose of weekly nab-paclitaxel compared with docetaxel.

38 r paclitaxel and 0.35 muM and 0.0087 muM for nab-paclitaxel compared with mitotane concentrations of

39 g/m(2) (49%) and 100 mg/m(2) (45%) weekly of nab-paclitaxel demonstrated a higher overall response ra

40 significant investigator ORR for both weekly nab-paclitaxel doses versus docetaxel.

41 h first-line treatment with gemcitabine plus NAB-paclitaxel, ECOG PS 0 to 1, and favorable comorbidit

42 uggest further investigation into the use of nab-paclitaxel for the treatment of ACC.

43 oped a platform technology that utilizes the nab-paclitaxel formulation of paclitaxel, Abraxane, in w

44 edian overall survival was 8.5 months in the nab-paclitaxel-gemcitabine group as compared with 6.7 mo

45 The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemci

46 ade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitab

47 gression-free survival was 5.5 months in the nab-paclitaxel-gemcitabine group, as compared with 3.7 m

48 In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3

49 H20 plus nab-paclitaxel/gemcitabine (PAG) or nab-paclitaxel/gemcitabine (AG).

50 omly assigned to treatment with PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) or nab-paclitaxel/gemci

51 ared with the control, native docetaxel, and nab-paclitaxel groups.

52 zumab plus chemotherapy with carboplatin and nab-paclitaxel in advanced NSCLC patients to explore pot

53 v-1 expression reduced uptake of albumin and nab-paclitaxel in cancer cells and rendered them resista

54 Selection for cellular resistance to nab-paclitaxel in cell culture correlated with a loss of

55 Further studies of nab-paclitaxel in combination with platinum are warrante

56 ed dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma a

57 We report efficacy and toxicity with nab-paclitaxel in this group.

58 ts of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in patients with recurrent platinum-sens

59 cusses the proposed mechanism of delivery of nab-paclitaxel, including an examination into a hypothes

60 cancer cells and rendered them resistant to nab-paclitaxel-induced apoptosis.

61 Patients were treated with NAB-paclitaxel intravenously during 30 minutes without c

62 Nab-paclitaxel is active in this group of patients with

63 ributing factor to the tumor accumulation of nab-paclitaxel is the binding of albumin to secreted pro

64 Nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) is an albumin-bound formulation of pacli

65 Recent data also suggest that nab-paclitaxel may enhance tumor accumulation of gemcita

66 o micromolar affinity for HSA Peptide 40 and nab-paclitaxel nanoparticles.

67 0 mg/m(2) of gemcitabine plus 125 mg/m(2) of nab-paclitaxel once a week for 3 weeks, every 28 days.

68 We compared nab-paclitaxel or ixabepilone once per week to paclitaxe

69 evaluate progression-free survival (PFS) for nab-paclitaxel or ixabepilone versus paclitaxel.

70 rs chose capecitabine, a taxane (paclitaxel, nab-paclitaxel, or docetaxel), gemcitabine, or vinorelbi

71 al of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcit

72 The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse ef

73 s with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved o

74 was increased by 2.8-fold in mice receiving nab-paclitaxel plus gemcitabine versus those receiving g

75 cacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based pacl

76 phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical a

77 atients with metastatic breast cancer (MBC), nab-paclitaxel produced significantly higher antitumor a

78 nab-Paclitaxel q3w versus docetaxel was not different fo

79 pporting this relationship between SPARC and nab-paclitaxel remain largely correlative at this point.

80 -1 protein levels correlated positively with nab-paclitaxel sensitivity.

81 For second-line therapy, gemcitabine plus NAB-paclitaxel should be offered to patients with first-

82 Paclitaxel and nab-paclitaxel show in vitro inhibition of H295R and SW-

83 Moreover, treatment with gemcitabine and nab-paclitaxel significantly reduces the overall number

84 bited resistance to the antitumor effects of nab-paclitaxel therapy.

85 with undergoing combination gemcitabine and nab-paclitaxel [time ratio (TR) = 1.26, 95% CI: 1.02-1.5

86 In vivo nab-paclitaxel treatment shows a greater decrease in tum

87 llax treatment, whereas native docetaxel and nab-paclitaxel treatments were ineffective.

88 The technology used to create nab-paclitaxel utilizes albumin to deliver paclitaxel, r

89 , 1.59; 95% CI, 1.31 to 1.93; P < .001), and nab-paclitaxel was not superior to paclitaxel (PFS, 9.3

90 nce per week was inferior to paclitaxel, and nab-paclitaxel was not superior with a trend toward infe

91 ian cumulative payments for gemcitabine with nab-paclitaxel were highest overall [median $74,051, int

92 n, blocks binding of all three antibodies to nab-paclitaxel when added in excess.

93 ng peripheral neuropathy, was increased with nab-paclitaxel, with more frequent and earlier dose redu